Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 24 of 24 publications.

La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796

Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J, Zhou X, Gnanasakthy A, Taylor K, Yusuf A, Maher I, Jamotte A, Kang YK. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer. ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095

Ayoub I, Bensink ME, Zhou X, Wang J, Gong W, Preciado P, Komers R, Inrig JK, Rheault MN, Tachtman H. Patient-reported outcomes in adults with FSGS: sparsentan vs. irbesartan. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):281.

Wadhwani S, Bensink M, Peipert JD, Ayoub I, Preciado P, Garbinsky D, Wang J, Choi J, Bennett L, Gong W, Inrig J, Komers R. Patient-reported outcomes in the PROTECT clinical trial comparing sparsentan with irbesartan for IgA nephropathy. Poster presented at the American Society of Nephrology (ASN) Kidney Week 2024; October 23, 2024. San Diego, CA. [abstract] J Am Soc Nephrol. 2024 Oct; 35(Suppl v1):723.

Gitomer BY, Chonchol M, Zhou X, Garbinsky D, Wang J, Nunna S, Fernandes AW, Oberdhan D. Kidney stone disease and progression risk in autosomal dominant polycystic kidney disease: a post hoc analysis of OVERTURE. Kidney360. 2024 Sep;5(9):1364-6. doi: 10.34067/KID.0000000000000524

Haug U, Morales DR, Ehrenstein V, Esen BO, Didelez V, Schafer W, Reinbold J, Martinez D, Garcia de Albeniz X, Gini R, Ryan O, Young J. Target trial emulation with real world evidence: regulatory grade pharmacoepidemiology in the SIGMA consortium. Presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.

Cid Royo A, Choi J, Plana E, Garcia Esteban R, Pajouheshnia R, Ryan O. A flexible open-source analytic pipeline for self-controlled analysis of real world data. Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.

Weibel D, De Luise C, Cid Royo A, Ryan O, Vaz T, Aguado J, Marsal J, Garcia de Albeniz Martinez X, Weinrib R, Yefimenko N, Pala E, Poblador-Plou B, Gimeno-Miguel A, Santos-Mejias A, Marconi E, Barbieri E, Stona L, Lysen T, Roy D, Hyeraci G, Girardi A, Lupattelli A, Desalegn AA, Villalobos F, Bissacco CA, Kendrick K, Garg R, Rubino H, Sturkenboom MCJM, Arana A. Interim results from the VAC4EU Post-Authorization Safety Study (PASS) among recipients of the Pfizer-BioNTech COVID-19 (Comirnaty®) vaccine in Europe. Poster presented at the 2024 ISPE Annual Meeting; August 27, 2024. Berlin, Germany.

Taieb J, Fakih M, Salvatore L, Esaki T, Modest DP, Paez D, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Wang J, Tran Q, Chao J, Chen Z, Pietrantonio F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. Poster presented at the ESMO 2024 Gastrointestinal Cancers Annual Congress; June 26, 2024. Munich, Germany.

Kluge F, Brand YE, Mico-Amigo ME, Bertuletti S, D'Ascanio I, Gazit E, Bonci T, Kirk C, Kuderle A, Palmerini L, Paraschiv-Ionescu A, Salis F, Soltani A, Ullrich M, Alcock L, Aminian K, Becker C, Brown P, Buekers J, Carsin AE, Caruso M, Caulfield B, Cereatti A, Chiari L, Echevarria C, Eskofier B, Evers J, Garcia-Aymerich J, Hache T, Hansen C, Hausdorff JM, Hiden H, Hume E, Keogh A, Koch S, Maetzler W, Megaritis D, Niessen M, Perlman O, Schwickert L, Scott K, Sharrack B, Singleton D, Vereijken B, Vogiatzis I, Yarnall A, Rochester L, Mazza C, Del Din S, Mueller A. Real-world gait detection using a wrist-worn inertial sensor: validation study. JMIR Form Res. 2024 May 1;8:e50035. doi: 10.2196/50035

Koch S, Peralta GP, Carsin AE, Abellan A, Roda C, Torrent M, Iniguez C, Ballester F, Ferrero A, Zabaleta C, Lertxundi A, Guxens M, Vrijheid M, Sunyer J, Casas M, Garcia-Aymerich J. Physical activity and body mass related to catch-up lung function growth in childhood: a population-based accelerated cohort study. Thorax. 2024 Mar 6;79(8):762-9. doi: 10.1136/thorax-2022-219666

Law EH, Sherif B, Mostaghimi A, King B, Sinclair R, Mesinkovshka N, Hanson KA, Korver D, Chirila C. Patients with alopecia areata treated with ritlecitinib have improved patient-reported emotional symptoms and activity limitations due to hair loss: post hoc analyses of ALLEGRO-2b/3. Poster presented at the Maui Derm Hawaii 2024; January 22, 2024. Wailea, HI.

Carsin AE, Garcia-Aymerich J, Accordini S, Dharmage S, Leynaert B, de Las Heras M, Casas L, Caviezel S, Demoly P, Forsberg B, Gislason T, Corsico AG, Janson C, Jogi R, Martinez-Moratalla J, Nowak D, Gomez LP, Pin I, Probst-Hensch N, Raherison-Semjen C, Squillacioti G, Svanes C, Toren K, Urrutia I, Huerta I, Anto JM, Jarvis D, Guerra S. Spirometric patterns in young and middle-aged adults: a 20-year European study. Thorax. 2024 Jan 18;79(2):153-62. doi: 10.1136/thorax-2022-219696

Moehler M, Wyrwicz L, Chen C, Davenport E, Wang J, Nathani R, Kondo K, Elimova E. Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N+C) vs (C). Poster presented at the 2024 German Cancer Congress (Deutscher Krebskongress); February 21, 2024. Berlin, Germany. [abstract] Oncol Res Treat. 2024; 41(Supple 1):65. Previously presented at the 2023 ASCO Annual Meeting.

Hamadani M, Spira AI, Zhou X, Liao L, Chen L, Radford J, Ai WZ, Solh MM, Ardeshna KM, Hess BT, Caimi PF, Stathis A, Carlo Stella C, Alderuccio JP, Kahl BS, Wang Y, Qin YG, Xu ZC, Zinzani PL. Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Adv. 2024 Jan;9(1):93-8. doi: 10.1182/bloodadvances.2023010636

Phillips C, White RP, Shugars DA, Zhou X. Risk factors associated with prolonged recovery and delayed healing after third molar surgery. J Oral Maxillofac Surg. 2003 Dec 1;61(12):1436-48.

Chromy J, Odom DM, Eyerman J, McNeeley M, Hughes A. The effect of interviewer experience on the interview process in the national survey on drug use and health. Poster presented at the Proceedings of the American Statistical Association, Section on Survey Research Methods; August 2003. San Francisco, CA.

Galant SP, Melamed IR, Nayak AS, Blake KV, Prillaman BA, Reed KD, Cook CK, Philpot EE, Rickard KA. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics. 2003 Jul;112(1 Pt 1):96-100. doi: 10.1542/peds.112.1.96

Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR. Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis. 2003 Apr 1;24(4):757-70.

Ascaso C, Garcia-Esteve L, Navarro P, Aguado J, Ojuel J, Tarragona MJ. Prevalencia de la depresión postparto en las madres españolas: comparación de la estimación mediante la entrevista clínica estructurada y la escala de depresión postparto de Edimburgo. Med Clin (Barc). 2003 Mar 15;120(9):326-9. doi: 10.1157 / 13044232

Prillaman BA, Kral KM. Multiple analyses, multiple populations, one outcome: lack of effect of fluticasone propionate on prepubescent growth. Poster presented at the AAAAI 60th Anniversary Meeting; March 7, 2003. Denver, CO. [abstract] J Allergy Clin Immunol. 2003 Feb 1; 111(2 Supplement 1):s73. doi: 10.1016/S0091-6749(03)80174-4

Garcia R, Benet M, Arnau C, Cobo E. Efficiency of cross-over relative to paralled group design. Poster presented at the 3rd Joint Meeting of the International Society for Clinical Biostatistics (ISCB) and Society for Clinical Trials (SCT); 2003. London, United Kingdom.

Nathan RA, Dorinsky P, Rosenzweig JRC, Shah T, Edin H, Prillaman B. Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent asthma. J Asthma. 2003;40(7):815-22. doi: 10.1081/jas-120023573

Steenbergen C, Afshari CA, Petranka JG, Collins J, Martin K, Bennett L, Haugen A, Bushel P, Murphy E. Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am J Physiol Heart Circ Physiol. 2003 Jan 1;284(1):H268-76.